读书笔记丨长三角肺癌之光-中国肺癌原创临床研究阶段汇总

发布于 2021-11-16 09:57 ，所属分类：知识学习综合资讯

读书笔记丨感恩并传承CTONG-中国肺癌原创临床研究

写意人物丨陆舜教授：从PI的角度看中国创新药的发展

陆舜教授：有的放矢，做肺癌研究领域的“领潮儿”

陆舜教授：沃利替尼有望成为首个代表中国走向全球的肺癌靶向创新药物

江浙沪地区历届重要肺癌论坛汇总（长三角地区肺癌论坛系列）

传承与发展丨长三角肺癌代表性著作汇总

传承与发展丨长三角肺癌协作组指南/专家共识汇总

读书笔记丨长三角肺癌科技成果奖励阶段汇总

直播课丨长三角肺癌协作组-罕见靶点临床试验招募全国巡讲系列汇总

光荣榜丨长三角肺癌协作组陆舜教授团队历届国际会议大会发言汇总

携手共赢丨长三角肺癌与知名药企临床研究合作成果阶段汇总

长三角肺癌协作组青年博士团队组织框架介绍

长三角肺癌之光丨星星之火可以燎原-基层肺癌协作组的前世今生

齐聚浙江嘉兴，长三角肺癌再续新篇章——浙江省基层肺癌协作组成立

长三角肺癌之光丨金陵肺癌传承与发展

长三角肺癌之光丨浙江肺癌传承与发展

杭州肺癌之光丨嘉兴肺癌（杭州肺癌-嘉兴支）传承与发展

光荣榜丨长三角肺癌-国科大支（杭州肺癌）国际会议大会发言汇总

历史回顾丨浙江省肿瘤医院胸部肿瘤青年医师精彩亮相2016WCLC

走进中国科学院大学附属肿瘤医院（浙江省肿瘤医院）I期临床试验病房

中国科学院大学附属肿瘤医院（浙江省肿瘤医院）I期临床试验病房进修人员招聘公告

长三角实体瘤病友交流群系列全面上线

● 中国原创肺癌●

●●●Original lung cancer of China●●●

J Clin Oncol（1篇），Lancet Respir Med（1篇），JAMA Oncol（1篇），Ann Oncol（1篇），J Thorac Oncol（5篇），Clin Cancer Res（2篇）

中国原创肺癌

Clin Cancer Res

Clin Cancer ResPyrotinib inHER2-amplified advanced non-small cell lung cancer: A prospective, multicenter, single-arm trialZheng-bo Song，Wen-xian Wang，Chun-wei Xu，Yi-ping Zhang，Shun Lu（2021）

J Thorac Oncol

J Thorac OncolSafety but limited efficacy of ensartinib in ROS1-positive non-smallcell lung cancer: A single-arm, multicenter phase II studyShun Lu（2021）

Lancet Respir Med

Lancet Respir MedOnce-daily savolitinib inChinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouringMETexon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 studyShun Lu（2021）

Transl Lung Cancer Res

Transl Lung Cancer ResFruquintinib with gefitinib as first-line therapy in patients carryingEGFR mutations with advanced non-small cell lung cancer: asingle-arm, phase II studyShun Lu（2021）

Ann Transl Med （TEINE, CTONG-0904）

Ann Transl MedDocetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trialShun Lu（2021）

J Thorac Oncol（RATIONALE 304）

J Thorac OncolTislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer (RATIONALE 304)：A randomized phase 3 trialShun Lu（2021）

J ThoracOncol

J Thorac OncolEfficacy and safety of niraparib as maintenance treatment in patients with extensive-stage small cell lung cancer after first-line chemotherapy：a randomized， double-blind，phase 3 study Shun Lu（2021）

JAMA Oncol（RATIONALE 307）

JAMA Oncol Tislelizumab plus chemotherapy vs chemotherapy aloneas first-line treatment for advanced squamous non-small-cell lung cancer：A phase 3 randomized clinical trialShun Lu（2021）

Lung Cancer

Lung CancerNivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)Shun Lu（2020）

Clin Cancer Res

Clin Cancer ResClonal architecture of EGFR mutation predicts the efficacy of EGFR-Tyrosine Kinase Inhitors in advanced NSCLC: a prospective multicenter study (NCT03059641)Shun Lu（2020）

Lung Cancer （FALUCA）

Lung CancerA phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer-the FALUCA studyShun Lu（2020）

J Thorac Dis

J Thorac DisCombination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trialYong Song（2019）

J Thorac Dis

J Thorac DisA phase II study of concurrent nab-paclitaxel/carboplatin combined with thoracic radiotherapy in locally advanced squamous cell lung cancerSheng-lin Ma（2019）

Am J Clin Oncol (RE-CHALLENGE，CTONG1304)

Am J Clin OncolEfficacy and safety of gefitinib as third-line treatment in NSCLC patients with activating EGFR mutations treated with first-line gefitinib followed by second-line chemotherapy：A single-arm, prospective, multicenter phase II study (RE-CHALLENGE, CTONG1304)Yong Song（2019）

J Clin Oncol

J Clin OncolRandomized, double-blind, placebo-controlled, multicenter phase II study of fruquintinib after two prior chemotherapy regimens in Chinese patients with advanced nonsquamous non-small-cell lung cancerShunLu（2018）

J Thorac Oncol

J Thorac OncolNedaplatin plus docetaxel versus cisplatin plus docetaxel as first-line chemotherapy for advanced squamous cell carcinoma of the lung-A multicenter, open-label, randomized, phase III trialShunLu（2018）

Onco Targets Ther

Onco Targets TherAfatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lungShun Lu（2018）

J Cancer

J CancerA randomized controlledstudy of rhTPO and rhIL-11 for the prophylactic treatment of chemotherapy-induced thrombocytopenia in non-small cell lung cancerShun Lu（2018）

Ann Oncol（East Asia S-1）

Ann OncolRandomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)ShunLu（2017）

BMC Cancer

BMC CancerA phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancerSheng-lin Ma（2016）

J Thorac Oncol

J Thorac OncolA multicenter, open-label, randomized phase II controlled study of rh-Endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancerShun Lu（2015）

Int J Hyperthermia

Int J HyperthermiaIntracavity hyperthermia in nasopharyngeal cancer: a phase III clinical studySheng-lin Ma（2010）

Acta Pharmacol Sin

Acta Pharmacol SinPhase II trial of gemcitabine plus cisplatin inpatients with advanced non-small cell lung cancerSheng-lin Ma（2010）

Chin Med J

Chin Med JGemcitabine and cisplatin treatment over a 3-week versus a 4-week dosing schedule: a randomized trial conducted in Chinese patients with nonsmall cell lung cancerMei-lin Liao（2008）

长三角肺癌沪浙苏临床试验三驱动一体化建设

临床试验-转化研究闭环式研究平台建设

1.基因多平台检测平台搭建（转化研究）

2.样本库平台搭建（转化研究）

3.罕见靶点类器官模型临床前研究平台搭建（临床试验+转化研究）

4.罕见靶点富集互联网医院平台搭建（临床试验+转化研究）

心路历程

心路历程1:2019.12 长三角肺癌协作组成立

心路历程2:2020.04 长三角肺癌协作组临床试验招募启动

心路历程3: 2020.07 长三角肺癌协作组青年医师巡讲团成立

心路历程4: 2021.01 长三角肺癌协作组青年博士团队成立

心路历程5:2021.03 江苏省基层肺癌协作组成立